6-amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3- b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor [4]

Journal of Medicinal Chemistry

Volumn 41, Issue 22, 1998, Pages 4196-4198

  Henry, James R ^a   Rupert, Kenneth C ^a   Dodd, John H ^a   Turchi, Ignatius J ^a   Wadsworth, Scott A ^a   Cavender, Druie E ^a   Fahmy, Bohumila ^a   Olini, Gilbert C ^a   Davis, Janet E ^a   Lee Pellegrino Gensey, J ^a   Schafer, Peter H ^a   Siekierka, John J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 AMINO 2 (4 FLUOROPHENYL) 4 METHOXY 3 (4 PYRIDYL) 1H PYRROLO[2,3 B]PYRIDINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 1; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRROLO[2,3 B]PYRIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LETTER; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

AMINOPYRIDINES; ANIMALS; ARTHRITIS, EXPERIMENTAL; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; ENZYME INHIBITORS; HUMANS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRROLES; RATS; RATS, INBRED LEW; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 7844222102     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980497b     Document Type: Letter

References (14)

1. Sawar, A.; Moore, T. L. Drug therapy of rheumatoid arthritis. Drugs Today 1997, 33, 299-306.
2. Brennan, F. M.; Feldman, M. Cytokines in autoimmunity. Curr. Opin. Immunol. 1996, 8, 872-877.
3. Camussi, G.; Lupia, E. The future of antitumor necrosis factor (TNF) products in the treatment of rheumatoid arthritis. Drugs 1998, 55, 613-620.
4. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265, 808-811.
5. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Keys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372, 739-746.
6. Gallagher, T. F.; Seibel, G. L.; Kassis, S.; Laydon, J. T.; Blumenthal, M. J.; Lee, J. C.; Lee, D.; Boehm, J. C.; Fier-Thompson, S. M.; Abt, J. W.; Soreson, M. E.; Smietana, J. M.; Hall, R. F.; Garigipati, R. S.; Bender, P. E.; Erhard, K. F.; Krog, A. J.; Hofmann, G. A.; Sheldrake, P. L.; McDonnell, P. C.; Kumar, S.; Young, P. R.; Adams, J. L. Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 1997, 5, 49-64.
7. Gallagher, T. F.; Fier-Thompson, S. M.; Garigipati, R. S.; Sorenson, M. E.; Smietana, J. M.; Lee, D.; Bender, P. E.; Lee, J. C.; Laydon, J. T.; Griswold, D. E.; Chabot-Fletcher, M. C.; Breton, J. J.; Adams, J. L. 2,4,5-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. 1995, 5, 1171-1176.
8. Markees, D. G.; Dewey, V. C.; Kidder, G. W. The synthesis and biological activity of substituted 2,6-diaminopyridines. J. Med. Chem. 1968, 11, 126-129.
9. Henry, J. R.; Dodd, J. H. Synthesis of RWJ 68354: A Potent Inhibitor of the MAP Kinase p38. Tetrahedron Lett. 1998, 39, in press.
10. Badger, A. M.; Bradbeer, J. N.; Votta, B.; Lee, J. C.; Adams, J. L.; Griswold, D. E. Pharmacological Profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J. Pharmacol. Exp. Ther. 1996, 279, 1453-1461.
11. 3 isodensity surface.
12. Wilson, K. P.; McCaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis, G. W.; Fitzgibbon, M. J.; Caron, P. R.; Murcko, M. A.; Su, M. S. S. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem. Biol. 1997, 4, 423-431.
13. Murray, J. S.; Ranganathan, S.; Politzer, P. Correlations between the solvent hydrogen bond acceptor parameter β, and the calculated molecular electrostatic potential. J. Org, Chem. 1991, 56, 3734-3737.
14. Krump, E.; Sanghera, J. S.; Pelech, S. L.; Furuya, W.; Grinstein, S. Chemotactic peptide N-formyl-Met-Leu-Phe activation of p38 mitogen-activated protein kinase (MAPK) and MAPK-activated protein kinase-2 in human neutrophils. J. Biol. Chem. 1997, 272, 937-944.